Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Standard of Care × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2 Genitourinary 2 Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Head and Neck Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 9 Mouth Neoplasms 6 Oropharyngeal Neoplasms 4 Laryngeal Neoplasms 4 Stomatitis 3 Head and Neck Carcinoma 3 Xerostomia 2 Lung Neoplasms 2 Hypopharyngeal Neoplasms 2 Carcinoma 2 Ulcer 1 Tonsillar Neoplasms 1 Tongue Neoplasms 1 Tobacco Use 1 Speech 1 Recurrence 1 Parotid Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Mucositis 1 Maxillary Sinus Neoplasms 1 Localized Head and Neck Carcinoma 1 Deglutition Disorders 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Anxiety Disorders 1

Interventions

Cetuximab 13 Gemcitabine 9 Cisplatin 9 pembrolizumab 8 Paclitaxel 7 Nivolumab 6 durvalumab 5 Docetaxel 5 toripalimab 4 Carboplatin 4 Valproic Acid 3 Fluorouracil 3 Capecitabine 3 tremelimumab 2 spartalizumab 2 nimotuzumab 2 irinotecan sucrosofate 2 cemiplimab 2 S 1 (combination) 2 Radiotherapy 2 Radiation 2 Methotrexate 2 Ipilimumab 2 Injections 2 Immune Checkpoint Inhibitors 2 Biopsy 2 18-O-demethylcervinomycin A2 2 vinflunine 1 tranilast 1 tislelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02369874 2021-02-10

EAGLE

AstraZeneca

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡